MedKoo Cat#: 326791 | Name: Tilbroquinol
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tilbroquinol is a quinoline-based antibiotics.

Chemical Structure

Tilbroquinol
CAS#7175-09-9

Theoretical Analysis

MedKoo Cat#: 326791

Name: Tilbroquinol

CAS#: 7175-09-9

Chemical Formula: C10H8BrNO

Exact Mass: 236.9789

Molecular Weight: 238.08

Elemental Analysis: C, 50.45; H, 3.39; Br, 33.56; N, 5.88; O, 6.72

Price and Availability

Size Price Availability Quantity
50mg USD 700.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Tilbroquinol
IUPAC/Chemical Name
7-Bromo-5-methylquinolin-8-ol
InChi Key
JMOVFFLYGIQXMM-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H8BrNO/c1-6-5-8(11)10(13)9-7(6)3-2-4-12-9/h2-5,13H,1H3
SMILES Code
OC1=C2N=CC=CC2=C(C)C=C1Br
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 238.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ekpenyong O, Gao X, Ma J, Cooper C, Nguyen L, Olaleye OA, Liang D, Xie H. Pre-Clinical Pharmacokinetics, Tissue Distribution and Physicochemical Studies of CLBQ14, a Novel Methionine Aminopeptidase Inhibitor for the Treatment of Infectious Diseases. Drug Des Devel Ther. 2020 Mar 30;14:1263-1277. doi: 10.2147/DDDT.S238148. PMID: 32280198; PMCID: PMC7127848. 2: Billet AC, Salmon Rousseau A, Piroth L, Martins C. An underestimated sexually transmitted infection: amoebiasis. BMJ Case Rep. 2019 May 10;12(5):e228942. doi: 10.1136/bcr-2018-228942. PMID: 31079045; PMCID: PMC6536245. 3: Nespola B, Betz V, Brunet J, Gagnard JC, Krummel Y, Hansmann Y, Hannedouche T, Christmann D, Pfaff AW, Filisetti D, Pesson B, Abou-Bacar A, Candolfi E. First case of amebic liver abscess 22 years after the first occurrence. Parasite. 2015;22:20. doi: 10.1051/parasite/2015020. Epub 2015 Jun 18. PMID: 26088504; PMCID: PMC4472968. 4: Desoubeaux G, Chaussade H, Thellier M, Poussing S, Bastides F, Bailly E, Lanotte P, Alison D, Brunereau L, Bernard L, Chandenier J. Unusual multiple large abscesses of the liver: interest of the radiological features and the real-time PCR to distinguish between bacterial and amebic etiologies. Pathog Glob Health. 2014 Jan;108(1):53-7. doi: 10.1179/2047773213Y.0000000121. Epub 2013 Dec 19. PMID: 24548161; PMCID: PMC4083168. 5: Fleck LE, North EJ, Lee RE, Mulcahy LR, Casadei G, Lewis K. A screen for and validation of prodrug antimicrobials. Antimicrob Agents Chemother. 2014;58(3):1410-9. doi: 10.1128/AAC.02136-13. Epub 2013 Dec 16. PMID: 24342644; PMCID: PMC3957891. 6: Guyon C, Greve E, Hag B, Cuilleron M, Jospe R, Nourrisson C, Raberin H, Tran Manh Sung R, Balique JG, Flori P. Abcès amibien hépatique avec récidive tardive en l'absence de séjour récent en zone d'endémie [Amebic liver abscess and late recurrence with no travel in an endemic area]. Med Sante Trop. 2013 Jul- Sep;23(3):344-6. French. doi: 10.1684/mst.2013.0189. PMID: 24026002. 7: Caroli-Bosc FX, Chichmanian RM, Caumes E, Saint-Paul MC, Marty P, Demarquay JF, Hastier P, Delmont JP. Hépatite aiguë due à l'association de tiliquinol et tilbroquinol (Intétrix) [Acute hepatitis caused by the combination of tiliquinol and tilbroquinol (Intétrix)]. Gastroenterol Clin Biol. 1996;20(6-7):605-6. French. PMID: 8881577. 8: Bougoudogo F, Fournier JM, Dodin A. Sensibilité in vitro de Vibrio cholerae du sérotype O:139 à un antiseptique intestinal l'association tiliquinol- tilbroquinol [In vitro sensitivity of Vibrio cholerae serotype 0:139 to an intestinal antiseptic tiliquinol-tilbroquinol combination]. Bull Soc Pathol Exot. 1994;87(1):38-40. French. PMID: 8003903. 9: Bougoudogo F, Fournier JM, Gastellu-Etchegorry M, Guillou M, Dodin A. Résistance de Vibrio cholerae O:1 au composé O/129 et multirésistance aux antibiotiques [Resistance of Vibrio cholerae 0:1 to the 0/129 compound and multiresistance to antibiotics]. Bull Soc Pathol Exot. 1992;85(2):136-41. French. PMID: 1327350. 10: Michel-Briand Y, Laporte JM, Plesiat P, Sansonetti PJ. Rôle des 4-quinolones et des antibiotiques dans l'élimination des plasmides de virulence des entérobactéries [The role of 4-quinolones and antibiotics in the elimination of virulence plasmids of Enterobacteriaceae]. Pathol Biol (Paris). 1987 Dec;35(10 Pt 2):1386-8. French. PMID: 3325901. 11: Michel-Briand Y, Laporte JM, Couetdic G, Sansonetti PJ. Elimination of a virulence plasmid from Shigella sonnei and Escherichia coli by antibiotics. Ann Inst Pasteur Microbiol. 1986 Nov-Dec;137B(3):291-5. doi: 10.1016/s0769-2609(86)80119-3. PMID: 3318870. 12: Basdevant A, Soffer M, Saragoussi JJ, Raison J, Pouillon M, Guy-Grand B. Neuropathie et atteinte oculaire après utilisation prolongée de tilbroquinol et de tiliquinol [Neuropathy and ocular involvement following prolonged use of tilbroquinol and tiliquinol]. Rev Med Interne. 1985 Jan;6(1):65-7. French. doi: 10.1016/s0248-8663(85)80081-3. PMID: 3923584. 13: Soffer M, Basdevant A, Sarragoussi JJ, Raison J, Guy-Grand B. Oxyquinoline toxicity. Lancet. 1983 Mar 26;1(8326 Pt 1):709. doi: 10.1016/s0140-6736(83)92000-7. PMID: 6132067.